Compare TCGL & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCGL | OVID |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.6M | 117.3M |
| IPO Year | 2025 | 2017 |
| Metric | TCGL | OVID |
|---|---|---|
| Price | $5.62 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.60 |
| AVG Volume (30 Days) | 662.9K | ★ 1.7M |
| Earning Date | 12-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,274,647.00 | ★ $6,610,000.00 |
| Revenue This Year | N/A | $1,081.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.80 | ★ 945.89 |
| 52 Week Low | $3.95 | $0.24 |
| 52 Week High | $5.91 | $2.01 |
| Indicator | TCGL | OVID |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.69 |
| Support Level | N/A | $1.21 |
| Resistance Level | N/A | $1.82 |
| Average True Range (ATR) | 0.00 | 0.15 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 63.29 |
TechCreate Group Ltd is a technology consultancy and advanced software solution provider offering a comprehensive range of payment, cybersecurity, and digital services and solutions. It serves large institutions, financial institutions and telecommunication companies, by providing them with payment, cybersecurity, and digital solutions such as, the development of RTE, RTP, API management and other services, such as cybersecurity defense, IT infrastructure, and cloud services. Its core business areas comprise: (1) the provision of professional services, (2) the sale of software licenses and maintenance licenses, and (3) the sale of hardware solutions.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.